Menopause Masterclass: Hormones, Brain Fog, Weight & Mental Health

Haver frames vaginal estrogen as essential skin care for the pelvic area. She notes that 30% of collagen is lost from skin in the first five years of menopause, contributing to thinning and fragility. Without estrogen, the urethra and vaginal introitus become more susceptible to mechanical trauma and infection. She recounts her personal story of delayed orgasm due to clitoral atrophy that resolved with vaginal estrogen, even though she was on systemic HRT. She also highlights that many clinicians erroneously believe vaginal estrogen carries the same risks as systemic estrogen, but the literature does not support that.

Haver underscores that even on optimal vaginal estrogen, tissues are still vulnerable. She compares it to applying moisturizer to skin—lubricant provides immediate slip and protection. She recommends having both a moisturizer (hyaluronic acid-based) for daily hydration and a lubricant for sexual activity.

Haver shares that due to age-related changes in labial anatomy, activities like hiking in loose shorts cause chafing. A moisturizer provides a barrier and hydration that prevents this irritation. She differentiates moisturizer from lubricant: moisturizer adds moisture over time, lubricant adds slipperiness for immediate friction reduction.

Haver details that first-line therapy for new mental health symptoms in perimenopause should be hormone therapy, not antidepressants. She criticises the outdated 2002 WHI study that scared clinicians and women away from HRT. She explains the difference between estradiol, estrone, estriol, and the importance of body-identical formulations. For women without a uterus, progesterone is optional but often helpful for sleep via GABA agonism. She notes that estrogen is FDA-approved for osteoporosis prevention and that nothing else holds that indication.

Haver recounts the disparity in education about testosterone, previously considered exclusively male. She now sees it as a hormone of homeostasis. She emphasises that testosterone is not a magic bullet for relationship issues; the partner must be someone the patient still loves and respects. She warns against pellet-only practices and high-pressure sales, advocating for affordable transdermal microdosing. She shares that even women who do not score clinically for HSDD may experience enhanced quality of life.

Haver mentions that even with busting my ass eating protein and lifting weights, her in-body scanner still flags low muscle mass because of genetics. However, she stresses that the objective is to keep her out of a nursing home by building reserves against sarcopenia and osteoporosis. This is part of her overall pillars of health that include hormone therapy, diet, exercise, stress reduction, and sleep.

Haver clarifies that many types of hormone therapy exist: oral, transdermal, vaginal, pellets. The problem with some pellet clinics is that they advertise that pellets will fix everything, charge high fees, and fail to offer safer, cheaper alternatives. She urges women to dig deeper and find providers who understand the full risk-benefit landscape and do not default to pellets alone. She quotes that only 8% of OB/GYN residents feel competent in menopause, making specialty menopause practitioners valuable.

Dr. Haver had been on systemic hormone therapy for about two years and assumed her genitourinary symptoms were covered. She used lubricants regularly and had no classical dryness or pain. Yet she noticed that reaching orgasm took longer and longer, causing significant frustration. Only after a conversation with her colleague Dr. Karen Men did she connect the dots: systemic estrogen wasn’t reaching the vulvovaginal tissues sufficiently. Within one month of adding vaginal estradiol as prescribed, her orgasmic function normalized. This personal revelation highlighted that GSM symptoms can be subtle and often go unreported, and that vaginal estrogen should be considered even in women on systemic HRT.

After measuring her own low muscle mass via in-body scanner and seeing naturally low testosterone levels for her age, Haver wondered whether replenishing testosterone to her 25-year-old levels could help her build or maintain muscle—a key factor in avoiding sarcopenia and frailty later in life. She had no libido complaints, and her validated HSDD screening would have been normal. Within a month of micro-dosing a men’s testosterone gel (one-tenth the male dose), she noticed an unexpected uptick in desire: her husband seemed more attractive, she initiated sex more often, and orgasm was no longer an issue thanks to concurrent vaginal estrogen. She emphasizes that she doesn’t sell testosterone and that her experience shouldn’t be misconstrued as pushing pellets; she simply now considers it a quality-of-life tool.

Haver describes how seeing the receptor distribution ‘took my breath away.’ Estrogen receptors in the brain, heart, bone, muscle, liver, joints, bladder, and skin mean that the withdrawal of estradiol at menopause triggers a cascade of inflammatory and metabolic changes across all those tissues. This explained why patients presented with frozen shoulder, arthralgias, elevated LDL, new-onset pre-diabetes, palpitations, and cognitive changes that she previously dismissed as unrelated. It cemented her commitment to educating clinicians and patients that menopause is a systemic state of estrogen deficiency with far-reaching consequences.

As ovarian egg supply dwindles to a critical threshold, the hypothalamus senses low estrogen and drives the pituitary to pump out more FSH and LH. The ovaries struggle to respond, creating a ‘zone of chaos’ in the brain. This neuroendocrine instability manifests as fatigue, sleep disruption, anxiety, depression, and a vague sense of ‘not feeling like myself,’ often years before periods change. Haver notes that in her practice she now recognizes patients as young as 35 presenting with these brain-first symptoms.

Haver argues that waiting until the vagina is dry, painful, or infected is akin to waiting for the skin to break before moisturizing. She states that all women in perimenopause and beyond should consider prophylactic vaginal estrogen. The vaginal tissue loses 30% of its collagen in the first five years postmenopause, and the microbiome protection against uropathogens wanes. Studies show no increased recurrence risk even in active breast cancer patients; in fact, survivors who used vaginal estrogen lived longer, likely due to prevention of deadly UTIs and sepsis. She stresses that the warning labels on systemic estrogen do not apply to local vaginal preparations.